dc.contributor.author | Peled, Nir | |
dc.contributor.author | Gillis, Roni | |
dc.contributor.author | Kılıçkap, Saadettin | |
dc.contributor.author | Froesch, Patrizia | |
dc.contributor.author | Orlov, Sergei | |
dc.contributor.author | Filippova, Elena | |
dc.contributor.author | Demirci, Umut | |
dc.contributor.author | Christopoulos, Petros | |
dc.contributor.author | Çiçin, İrfan | |
dc.contributor.author | Buğdaycı Basal, Fatma | |
dc.contributor.author | Yılmaz, Cengiz | |
dc.contributor.author | Fedor, Moiseenko | |
dc.contributor.author | Korkmaz, Taner | |
dc.contributor.author | Paydaş, Semra | |
dc.contributor.author | Gautschi, Oliver | |
dc.contributor.author | Zırtıloğlu, Alişan | |
dc.contributor.author | Eralp, Yeşim | |
dc.contributor.author | Yeşil Çınkır, Havva | |
dc.contributor.author | Sezer, Ahmet | |
dc.contributor.author | Erman, Mustafa | |
dc.contributor.author | Tural, Deniz | |
dc.contributor.author | Turna, Hande | |
dc.contributor.author | Mazieres, Julien | |
dc.contributor.author | Dudnik, Elizabeth | |
dc.contributor.author | Reguart, Noemi | |
dc.contributor.author | Camidge, David Ross | |
dc.contributor.author | Ng, Terry L. | |
dc.contributor.author | Çay Şenler, Filiz | |
dc.contributor.author | Beypınar, İsmail | |
dc.contributor.author | Yazılıtaş, Doğan | |
dc.contributor.author | Demirkazık, Ahmet | |
dc.contributor.author | Karaoğlu, Aziz | |
dc.contributor.author | Okutur, Kerem | |
dc.contributor.author | Coşkun, Hasan Şenol | |
dc.contributor.author | Şendur, Mehmet Ali Nahit | |
dc.contributor.author | Işıkdoğan, Abdurrahman | |
dc.contributor.author | Çabuk, Devrim | |
dc.contributor.author | Yumuk, Perran Fulden | |
dc.contributor.author | Yıldız, İbrahim | |
dc.contributor.author | Kaplan, Mehmet Ali | |
dc.contributor.author | Özyılkan, Özgür | |
dc.contributor.author | Öztop, İlhan | |
dc.contributor.author | Ölmez, Ömer Fatih | |
dc.contributor.author | Aydın, Kübra | |
dc.contributor.author | Aydıner, Adnan | |
dc.contributor.author | Meydan, Nezih | |
dc.contributor.author | Grinberg, Roxana Denisa | |
dc.contributor.author | Roisman, Laila C. | |
dc.date.accessioned | 2020-10-16T10:52:57Z | |
dc.date.available | 2020-10-16T10:52:57Z | |
dc.date.issued | 2020 | en_US |
dc.identifier.citation | Peled, N., Gillis, R., Kılıçkap, S., Froesch, P., Orlov, S., Filippova, E. ... Roisman, L. C. (2020). Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients. Lung cancer, 148, 48-54. https://dx.doi.org/10.1016/j.lungcan.2020.07.022 | en_US |
dc.identifier.issn | 0169-5002 | |
dc.identifier.issn | 1872-8332 | |
dc.identifier.uri | https://dx.doi.org/10.1016/j.lungcan.2020.07.022 | |
dc.identifier.uri | https://hdl.handle.net/20.500.12511/5930 | |
dc.description.abstract | Lorlatinib is a third-generation tyrosine-kinases inhibitor (TKI) targeting ALK/ROS1 fusions. The FDA has approved lorlatinib for TKI-pretreated ALK(+) NSCLC, while its approval for ROS1( + ) is still pending. Here we present the largest real-world data of NSCLC patients harboring ALK/ROS1 rearrangements treated with lorlatinib.Methods: 123 patients were enrolled retrospectively (data cut-off 1/1/2019). Lorlatinib was administered through an early access program for patients with no other available therapy. Outcome and response were defined by each investigator upon RECIST 1.1 criteria.Results: 106 ALK(+) and 17 ROS1(+) patients recruited from 8 different countries. The ALK( + ) cohort included 50 % males, 73 % never-smokers and 68 % with brain metastases. Extracranial (EC) and intracranial (IC) response rates (RR) were 60 % and 62 %, with disease control rates (DCR) of 91 % and 88 % respectively. Mean duration of therapy (DoT) was 23.9 +/- 1.6 months and median overall survival (mOS) was 89.1 +/- 19.6 months. ROS1 cohort enrolled 53 % males, 65 % never-smokers and 65 % had brain metastases. EC and IC RR were 62 % and 67 % with DCR of 92 % and 78 % respectively. Median DoT was 18.1 +/- 2.5 months and mOS of 90.3 +/- 24.4 months. OS and DoT in both cohorts were not significantly correlated with line of therapy nor other parameters.The most common adverse events of any grade were peripheral edema (48 %), hyperlipidemia (47 %), weight gain (25 %) and fatigue (30 %). CNS adverse events such as cognitive effect of grade 1-2 were reported in 18 % of patients.Conclusion: Lorlatinib shows outstanding EC/IC efficacy in ALK/ROS1(+) NSCLC. The observed mOS of 89 +/- 19 months in ALK(+) NSCLC supports previous reports, while mOS from of 90 +/- 24 months is unprecedented for ROS1( + ) NSCLC. | en_US |
dc.description.sponsorship | Pfizer | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier Ireland Ltd | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.subject | Lorlatinib | en_US |
dc.subject | Real-World Data | en_US |
dc.subject | ALK | en_US |
dc.subject | ROS1 | en_US |
dc.title | Glass: Global lorlatinib for ALK(+) and ROS1(+) retrospective study: Real world data of 123 NSCLC patients | en_US |
dc.type | article | en_US |
dc.relation.ispartof | Lung cancer | en_US |
dc.department | İstanbul Medipol Üniversitesi, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı | en_US |
dc.authorid | 0000-0001-7934-7039 | en_US |
dc.identifier.volume | 148 | en_US |
dc.identifier.startpage | 48 | en_US |
dc.identifier.endpage | 54 | en_US |
dc.relation.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
dc.identifier.doi | 10.1016/j.lungcan.2020.07.022 | en_US |
dc.identifier.wosquality | Q1 | en_US |
dc.identifier.scopusquality | Q1 | en_US |